We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+18.23%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$158M
Cap. Flow
+$36.7M
Cap. Flow %
2.84%
Top 10 Hldgs %
39.6%
Holding
109
New
17
Increased
24
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$36.8M
2
SNY icon
Sanofi
SNY
+$29.7M
3
QDEL icon
QuidelOrtho
QDEL
+$27.8M
4
KRYS icon
Krystal Biotech
KRYS
+$17.5M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$24.3M
2
NRIX icon
Nurix Therapeutics
NRIX
+$22.4M
3
PEN icon
Penumbra
PEN
+$22.2M
4
HUM icon
Humana
HUM
+$16.6M
5
GSK icon
GSK
GSK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
51
Enliven Therapeutics
ELVN
$4.42B
$6.12M 0.47%
239,705
-529,558
-69% -$12.3M
BLCO icon
52
Bausch + Lomb
BLCO
$5.84B
$6.02M 0.47%
+312,000
New +$5.16M
THTX
53
DELISTED
Theratechnologies
THTX
$5.95M 0.46%
4,801,376
– –
ERAS icon
54
Erasca
ERAS
$6.34B
$5.9M 0.46%
2,162,162
– –
APLT
55
DELISTED
Applied Therapeutics
APLT
$5.79M 0.45%
680,784
-588,930
-46% -$3.47M
ADPT icon
56
Adaptive Biotechnologies
ADPT
$3.75B
$5.7M 0.44%
1,112,749
-607,251
-35% -$2.65M
ARVN icon
57
Arvinas
ARVN
$568M
$5.64M 0.44%
+228,800
New +$5.97M
ALEC icon
58
Alector
ALEC
$203M
$5.63M 0.44%
1,207,371
-1,031,635
-46% -$5.53M
ENGN icon
59
enGene Therapeutics
ENGN
$121M
$5.28M 0.41%
800,000
– –
YMAB
60
DELISTED
Y-mAbs Therapeutics
YMAB
$5.26M 0.41%
399,982
-248,000
-38% -$3.14M
TMCI icon
61
Treace Medical Concepts
TMCI
$284M
$5.15M 0.4%
887,941
-1,477,707
-62% -$9.49M
SLN
62
Silence Therapeutics
SLN
$554M
$4.73M 0.37%
+260,000
New +$4.84M
BCAB icon
63
BioAtla
BCAB
$5.53M
$4.43M 0.34%
50,350
-27,676
-35% -$2.32M
DYN icon
64
Dyne Therapeutics
DYN
$4.83B
$4.22M 0.33%
117,500
-83,500
-42% -$3.32M
PODD icon
65
Insulet
PODD
$9.66B
$3.9M 0.3%
16,750
-2,050
-11% -$421K
NARI
66
DELISTED
Inari Medical, Inc. Common Stock
NARI
$3.87M 0.3%
93,878
-314,495
-77% -$15.1M
NTRA icon
67
Natera
NTRA
$38B
$3.8M 0.29%
29,900
+26,300
+731% +$3.02M
NSPR icon
68
InspireMD
NSPR
$33.8M
$3.69M 0.29%
1,378,128
– –
MREO
69
Mereo BioPharma
MREO
$48.8M
$3.48M 0.27%
846,953
-400,000
-32% -$1.65M
CALC icon
70
CalciMedica
CALC
$11.2M
$3.47M 0.27%
783,904
– –
ABBV icon
71
AbbVie
ABBV
$431B
$3.11M 0.24%
+15,750
New +$2.94M
PCVX icon
72
Vaxcyte
PCVX
$8.76B
$3.09M 0.24%
27,050
-158,200
-85% -$14.3M
TNGX icon
73
Tango Therapeutics
TNGX
$4.72B
$2.64M 0.2%
343,152
-706,743
-67% -$6.74M
ESTA icon
74
Establishment Labs
ESTA
$2.33B
$2.57M 0.2%
59,400
+44,400
+296% +$1.93M
MDXH icon
75
MDxHealth
MDXH
$22.5M
$2.3M 0.18%
+1,105,000
New +$3M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Soleus Capital Management held 109 positions worth $1.29B, up 14% from $1.13B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Soleus Capital Management's Q3 2024 filing shows 17 new, 24 increased, 36 reduced and 22 closed positions. Its largest new stake was Grifois: 4,521,703 shares worth $40.2M. The largest sale was TG Therapeutics, an estimated $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

  • Soleus Capital Management's largest Q3 2024 buy was Grifois: 4,521,703 shares worth $40.2M.
  • Soleus Capital Management added most to Sanofi in Q3 2024, an estimated $29.7M increase.
  • Soleus Capital Management's biggest Q3 2024 reduction was TG Therapeutics, cutting an estimated $24.3M.
  • Soleus Capital Management fully exited Penumbra in Q3 2024, selling an estimated $22.2M.
  • Soleus Capital Management's ten largest holdings make up 40% of its $1.29B portfolio in Q3 2024.
  • Soleus Capital Management opened 17 new positions and closed 22 in Q3 2024.
  • Soleus Capital Management's portfolio value rose 14% quarter-over-quarter to $1.29B.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.